sou

We would like to express our sincere gratitude to all of you, our valued customers, for your continued support.

I would also like to express my deepest appreciation to healthcare professionals and all those who continue to work on the front line during the ongoing COVID-19 pandemic.

The repeated spread of infection has completely changed our lifestyle. In this new normal, we are gradually establishing new communication methods that are rooted in the common understanding that controlling the flow of people is important for infection control and that large-scale events and opportunities for interacting with others must be avoided. Virtual exhibitions and webinars that make full use of digital technologies have proven to be useful methods for providing information to a wide range of customers while minimizing contact. However, unlike the days before the COVID-19 pandemic, we are now unable to obtain the information that can be only communicated through face-to-face interaction. I feel that we all need to remind ourselves once again of the importance of the connections that may have been weakened by the adoption of new and efficient communication tools.
The foundation of this company has always been in the partnerships we build with our customers. Our webinars, in addition to providing the latest clinical information, will be transformed into occasions during which we can communicate with our customers to strengthen the partnerships that embody our Made for Life concept.

Recently, we published a news release about the commencement of collaborative research with National Cancer Center Japan on photon counting computed tomography (PCCT), a next-generation diagnostic imaging technique. PCCT is expected to be capable of identifying multiple material components with improved resolution while minimizing exposure dose. The introduction of PCCT into clinical practice has been long-awaited by research institutions all over the world. It is a technology that holds the possibility of realizing dramatic improvements in clinical value, ranging from prevention and diagnosis of diseases to treatment and prognostic management.
Canon Medical Systems will continue to work together with the Exploratory Oncology Research & Clinical Trial Center and Hospital East of National Cancer Center Japan to create innovative healthcare systems and contribute to the development of advanced medical care.


Toshio Takiguchi
President and CEO

President's Message

 
Contact Us